Verve Therapeutics, Inc.

NASDAQ:VERV

5.64 (USD) • At close December 31, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019
Operating Activities:
Net Income -200.068-157.387-120.314-45.704-19.297
Depreciation & Amortization 5.4552.8041.5351.3280.106
Deferred Income Tax 001.5080.38-0.072
Stock Based Compensation 35.11622.4777.0720.850.446
Change In Working Capital 17.7038.38-2.9122.6422.661
Accounts Receivables 0-1.012000
Inventory 01.012000
Accounts Payables 3.91-5.2166.829-1.8981.735
Other Working Capital 13.79313.596-9.7414.540.926
Other Non Cash Items -7.7551.39435.2315.2398.714
Operating Cash Flow -149.549-122.332-77.88-35.265-7.442
Investing Activities:
Investments In Property Plant And Equipment -9.283-13.232-4.359-3.424-1.857
Acquisitions Net 0142.723234.73947.70310.901
Purchases Of Investments -517.14-479.401-371.494-98.484-22.001
Sales Maturities Of Investments 554.113336.678136.75550.78111.1
Other Investing Activites 0-142.723-234.739-47.703-10.901
Investing Cash Flow 27.69-155.955-239.098-51.127-12.758
Financing Activities:
Debt Repayment 00000
Common Stock Issued 210.456326.495285.21492.62718.04
Common Stock Repurchased 00000
Dividends Paid 00000
Other Financing Activities 2.1212.46191.87592.62717.954
Financing Cash Flow 212.577328.956377.08992.62717.954
Other Information:
Effect Of Forex Changes On Cash 00000
Net Change In Cash 90.71850.66960.1116.235-2.246
Cash At End Of Period 210.954120.23669.5679.4563.221